清热祛湿法治疗活动期溃疡性结肠炎的实验和临床研究
|
摘要
研究目的、意义
近年来溃疡性结肠炎(ulcerative colitis,UC)在我国的发病率呈逐渐升高趋势,且被认为是结肠癌的癌前病变,已被世界卫生组织列为现代难治病之一。因其病因和发病机制尚未完全阐明,目前尚无根治办法。西药治疗本病,存在着疗效不理想及副作用较大等缺点,影响了病人的依从性,因此努力寻找临床疗效显著且副作用小的治疗方法是当务之急。在全面总结前期大量临床研究和实验研究的基础上,我们提出UC的病机特点,活动期以大肠湿热为主,治疗当以清热祛湿为主;缓解期病机特点以脾胃气虚为主,治疗当以健脾益气为主,而气滞血瘀贯穿病程始终。为了凸现中医药治疗本病的特色及优势,我们以UC轻中度病例为突破口,对活动期UC予清热祛湿中药口服+保留灌肠,形成肠炎清1号方和肠涤清灌肠液,并将其作为院内制剂在广东省中医院使用十余年,临床疗效显著。近年来研究发现,氧自由基参与了UC疾病的发生发展过程,本研究通过动物实验观察清热祛湿法(肠涤清灌肠+肠炎清1号灌胃)对实验性UC大鼠结肠黏膜损伤指数、血清和结肠组织匀浆SOD活力和MDA含量的影响,探讨其作用机制;同时采取随机对照前瞻性的临床研究,对清热祛湿法治疗活动期轻中度大肠湿热型UC的临床疗效及其安全性作出科学评价,探索治疗本病的最佳方案,以进一步推广其在临床应用。
研究方法
本课题分为实验研究和临床研究两部分。
实验研究方法:选择SPF级健康成年雌性SD大鼠51只,先随机抽取8只大鼠作为正常组,不予造模,剩余的43只大鼠利用三硝基苯磺酸(TNBS)+乙醇溶液诱导出急性期UC大鼠模型,造模后第3天随机抽取2只解剖以观察造模是否成功。剩余的41只大鼠随机分为4组:模型组(空白组)11只;肠涤清组、肠涤清+肠炎清组、SASP组,每组10只。造模后第4天开始用药,正常组和模型组大鼠每日给予生理盐水灌胃+灌肠,其余3组分别给予肠涤清灌肠、肠涤清灌肠+肠炎清灌胃、SASP灌胃+灌肠治疗,疗程结束后观察大鼠一般情况、体重、结肠黏膜损伤指数、光镜下结肠黏膜病理形态、血清和结肠组织匀浆SOD活力及MDA含量的变化。疗程为2周。
临床研究方法:将符合纳入标准的活动期轻、中度大肠湿热型UC患者70例,随机分为治疗组35例,对照组35例。治疗组予肠炎清1号方口服+肠涤清灌肠,对照组予SASP口服+灌肠,观察两组患者治疗前后的临床症状及体征(包括腹泻、粘液血便、里急后重等)、舌象、脉象、ESR、CRP、大便潜血及结肠镜黏膜病变特点。疗程为4周。
研究结果
1实验研究结果
1.1大鼠一般情况改善:所有大鼠在造模后的第2天即出现稀烂便,随后相继出现粘液便、脓血便。模型组大鼠伴有反应迟钝,不喜活动,倦怠懒动、毛发凌乱、拱背、饮食饮水减少、体重减轻,甚至死亡现象。其他3个治疗组用药1周后大鼠粘液血便逐渐减少,活动逐渐增多,饮食饮水量逐渐增加,其中以肠涤清+肠炎清组大鼠症状改善最为显著。
1.2大鼠体重变化:肠涤清组与肠涤清+肠炎清组大鼠体重增长均较快,两组比较差异无统计学意义(P＞0.05);肠涤清组与肠涤清+肠炎清组大鼠体重增长同SASP组比较,差异均有统计学意义(P＜0.01);SASP组大鼠体重增长和模型组比较,差异无统计学意义(P＞0.05),SASP组大鼠体重增长较慢。
1.3大鼠结肠黏膜损伤指数(CMDI)变化:CMDI以模型组为最高,与正常组比较,差异有统计学意义(P＜0.01);经过治疗后3个用药组CMDI均有所下降,与模型组比较,差异均有统计学意义(P＜0.01);肠涤清+肠炎清组CMDI与肠涤清组、SASP组比较,差异均有统计学意义(P＜0.01);肠涤清组和SASP组CMDI比较,差异无统计学意义(P＞0.05)。
1.4大鼠血清和结肠组织匀浆SOD活力变化:各组大鼠血清和结肠组织匀浆SOD活力从高到低,依次为:正常组＞肠涤清+肠炎清组＞肠涤清组＞SASP组＞模型组,其中以肠涤清+肠炎清组大鼠SOD活力升高最为显著(与其他3组比较,均P＜0.01)。
1.5大鼠血清和结肠组织匀浆MDA含量变化:各组大鼠血清和结肠组织匀浆MDA含量从高到低,依次为:模型组＞SASP组＞肠涤清组＞肠涤清+肠炎清组＞正常组,其中以肠涤清+肠炎清组MDA含量下降最为显著(与其他3组比较,P＜0.05或P＜0.01)。
2临床研究结果
2.1治疗后两组患者ESR、CRP比较:治疗组有21例患者、对照组有22例患者复查ESR、CRP。治疗后两组患者ESR和CRP都有所下降,与治疗前比较,差异均有统计学意义(P＜0.05或P＜0.01)。治疗后,两组ESR比较,差异有统计学意义(P＜0.05),治疗组ESR降低优于对照组;两组CRP比较,差异无统计学意义(P＞0.05),两组疗效相当。
2.2治疗后两组患者大便潜血改善比较:对大便潜血的改善情况,治疗组优于对照组(P＜0.05)。
2.3治疗后两组患者主要症状积分比较:治疗组所有症状均有改善,与治疗前比较,差异均有统计学意义(P＜0.05或P＜0.01);对照组除肛门灼热和溲赤2个症状改善不明显外,其余6个症状均有改善,与治疗前比较,差异有统计学意义(P＜0.05或P＜0.01)。治疗后两组患者症状积分改善比较,治疗组对里急后重和溲赤症状的改善优于对照组(P＜0.01);而其它6个症状(腹泻、粘液血便、腹痛、腹胀、发热、肛门灼热)的改善,两组比较无显著性差异(P＞0.05)。
2.4两组患者中医证候疗效比较:治疗组临床痊愈7例,显效10例,有效12例,无效2例,总有效率为92.5%;对照组临床痊愈2例,显效5例,有效14例,无效9例,总有效率为70.0%,治疗组中医证候疗效优于对照组(P＜0.01)。
2.5治疗后两组患者结肠黏膜病变情况比较:治疗组有15例患者,对照组有18例患者复查肠镜,治疗组对结肠黏膜病变的改善优于对照组(P＜0.05)。
2.6两组患者临床综合疗效比较:治疗组完全缓解6例,显效9例,好转12例,无效4例,总有效率为87.1%;对照组完全缓解3例,显效4例,好转15例,无效8例,总有效率为73.3%,治疗组临床综合疗效优于对照组(P＜0.05)。
2.7临床综合疗效与病变范围、病情严重程度的相关性分析:临床综合疗效与病变范围无相关性(P＞0.05),与病情严重程度呈正相关(P＜0.01),病情越轻,临床疗效越显著。
2.8不良反应观察:用药期间治疗组未见明显毒副作用,对照组有1例患者出现白细胞减少,疗程结束后停用西药,未做特殊处理。
研究结论
1肠涤清+肠炎清可以显著改善UC大鼠的腹泻和便血情况,减轻结肠黏膜损伤指数,改善结肠黏膜的病理形态学情况,提高血清和结肠组织SOD活力,降低血清和结肠组织MDA含量。
2清热祛湿法治疗活动期轻中度大肠湿热型UC疗效确切,可以显著降低UC患者ESR,改善大便潜血、主要症状和结肠黏膜病变程度,中医证候疗效和临床综合疗效优于西药对照组。结合动物实验结果,考虑清热祛湿法治疗活动期UC的机制之一,在于减轻机体的脂质过氧化强度,提高血清和结肠组织中SOD活力,降低血清和结肠组织中MDA含量,从而增强对细胞的保护作用,促进炎症和溃疡的愈合。
Objective and Significance:
The incidence of ulcerative colitis(UC) has been steadily increased in China since last decades.UC has been considered as precancerous lesions of colon cancers and classified as one of refractory diseases in modern society by World Health Organization.The etiology and pathogenesis of UC have not been fully elucidated,so there is no radical treatment for UC.Treatment of UC by western medicine has some shortcomings,such as unsatisfied efficacy and considerable side effects,which reduce patients' compliance.Therefore, it urgently needs to find alternative treatments with significant clinical improvement and little adverse effects.Based on the results from large amounts of previous clinical and experimental studies,we propose the pathogenesis of UC from the Chinese traditional medicine point of view.The characteristic of active UC is mainly wetness-heat of large intestine while that of remission stage is largely deficiency of spleen-Qi and stomach-Qi.Treatment for the former is dependent on removing heat and dispersing dampness but treatment for the latter should strengthen the spleen and replenish Qi.Both acute and remission stages of UC have Qi-stagnancy and blood stasis.Chinese traditional medicines were applied to treat patients with mind and moderate UC which can reflect on their characteristics and advantages.Patients with UC at acute stage were treated with a combination of oral Changyanging 1 and enema Changdiging fluid.Both Changyanging 1 and Changdiging fluid have been used in TCM hospital of Guangdong province for more than 10 years.
Recent studies have demonstrated that oxygen-free radicals play a role in the pathogenesis of UC.To explore the therapeutic effects and mechanisms, we measured the effect of removing heat and dispersing dampness(treatment by combination of oral Changyanging 1 and enema Changdiging fluid) on colon mucosa damage index(CMDI),the dynamic changes of superoxide dismutase(SOD) activity and MDA level in serum and colon tissues of rats with experimental ulcerative colitis.By means of randomized controlled prospective clinical study,we also evaluated the clinical efficacy and safety of the combination of Changyanqing 1 and Changdiqing fluid in the treatment of UC.Results from these studies,we could demonstrate their effectiveness on the treatment of UC and facilitate their clinical application.
Methods:
This thesis included two parts:experiment study and clinical study.
Methods of experimental study:8 rats were randomly selected as the normal group from 51 healthy female Sprague-Dawley(SD) rats.Active UC was induced by trinitro-benzene-sulfonic acid(WNBS) and ethanol solution in 43 rats.Three days after establishing the model of UC,2 rats randomly selected were dissected in order to observe the success of model.The remainders(41 rats) were randomly divided into three model groups,i.e.,Changdiqing group, Changdiqing + Changyanqing group and salicylazosulfapyridine(SASP) group.Four days after establishing the model of UC,the rats in both normal and model groups were treated with normal Saline enema(NSE).Rats in the other 3 groups were treated with Changdiqing enema,Changdiqing enema plus Changyanqing garage,and SASP by gavage and enema,respectively.The protection mechanism of the method of removing heat and dispersing dampness was observed in terms of general condition,weight,CMDI,dynamic changes of SOD activity and MDA level in serum and tissues of colon.The course of treatment was 2 weeks.
Methods of clinical study:Seventy patients fulfilling the inclusion criteria were randomly divided into two groups.Thirty-five cases in experimental group were treated with the combination of oral Changyanqing 1 and enema Changdiqing fluid,while 35 cases in control group were treated with SASP by oral administration and enema.The clinical efficacies were evaluated by observing patients with clinical symptoms and signs(including diarrhea, mucous bloody stool,rectal tenesmus,etc.),the characteristics of tongue and pulse,by measuring ESR and CRP,and by detecting fecal occult blood and colon mucous.The course of treatment was 4 weeks.
Results:
1 The results of experimental study:
1.1 The improvement of general conditions in rats:Two days after establishing the model of UC,all rats had loose stools,followed by mucous stool and bloody purulent stool.Rats in model group were companied with slow response,lack of movement,tiredness,messy hair,hollow back,poor appetite and little drinking-water,lose weight,and even death.One week after medication,mucous bloody stool gradually reduced while physical activities gradually improved. Both diet-uptake and drinking-water were gradually increased in the rats of other three treatment groups.The improvement of symptoms was most significant in Changdiqing + Changyanqing group.
1.2 Weight changes in rats:The weight of rats had rapid growth in Changdiqing group and Changdiqing + Changyanqing group,but there was no significant difference in weight change between these groups(P＞0.05).Comparing Changdiqing group with SASP group,a significant difference in weight change was noted(P＜0.01).Comparing Changdiqing + Changyanqing group with SASP group, the difference in weight change was also statistically significant (P＜0.01).Comparing SASP group with model group,no significant difference in weight change was found(P＞0.05).Rats grew slower in SASP group.
1.3 CMDI changes in rats:CMDI was highest in model group,compared with normal group,the difference was statistically significant(P＜0.01).After treatment,CMDI declined in 3 treatment groups.Comparing the 3 treatment groups with model group,the differences were statistically significant (P＜0.01).Comparing Changdiqing + Changyanqing group with Changdiqing group and SASP group,the differences were statistically significant (P＜0.01).Comparing Changdiqing group with SASP group,no significant difference in CMDI was noted(P＞0.05).
1.4 Dynamic changes of SOD activity in rats serum and tissues of colon:Normal group had highest SOD activity,followed by Changdiqing + Changyanqing group, Changdiqing group,SASP group,and untreated model group.The increase of SOD activity was the most remarkable in Changdiqing + Changyanqing group,compared with the other 3 groups,the difference was statistically significant(P＜0.01).
1.5 Dynamic changes of MDA level in rats serum and tissues of colon:Dynamic changes of MDA level was as follows:model group＞SASP group＞Changdiqing group＞Changdiqing + Changyanqing group＞normal group.The decline of MDA level was the most notable in Changdiqing + Changyanqing group,compared with the other 3 groups,the differences were statistically significant(P＜0.05 or P＜0.01).
2 The results of clinical study:
2.1 The result of ESR,CRP:Twenty-one patients in treat group completed the measurements of ESR and CRP after treatment,while 22 patients in control group did.After treatment,both ESR and CRP were decreased when compared to those before treatment(P＜0.05 and P＜0.01 for ESR and CRP,respectively).ESR was significantly low in treated groups if compared to that in control group (P＜0.05).However,CRP had no significant change between treated and control groups.
2.2 The detection of fecal occult blood showed that the treat group was superior to the control group(P＜0.05).
2.3 Scoring for major symptoms:In treated group all symptoms have improved, compared to those before treatment,the differences were statistically significant(P＜0.05 or P＜0.01) In control group,in addition to rectum searing heat and short red urine,the improvement of other 6 symptoms were compared with before treatment,the difference was statistically significant (P＜0.05 or P＜0.01).After treatment,the improvement of rectal tenesmus and short red urine,the treat group was superior to the control group(P＜0.01).The improvement of other 6 symptoms,comparing the two groups,the difference was not statistically significant(P＞0.05).
2.4 Syndromes judged by Chinese traditional medicine standards:In treated group,among the 31 cases,7 cases were cured,lO cases were markedly effective, 12 cases were effective and 2 cases were ineffective,the total effective rate was 92.5%.As for control group,among the 30 cases,2 cases were cured, 5 cases were markedly effective,14 cases were effective and 9 cases were ineffective,the total effective rate was 70.0%.The treat group was superior to the control group in term of Chinese medicine syndromes efficacy(P＜0.05).
2.5 The result of examining colon mucosal lesions:Fifteen patients in treat group received colonoscopy after treatment,while18 patients in control group did.Pathologic examination showed that colon mucosal lesions in the treated group improved better than that in the control group(P＜0.05).
2.6 The result of clinical comprehensive efficacy:In treated group,among the 31 cases,6 cases were cured,9 cases were markedly effective,12 cases were effective and 4 cases were ineffective,the total effective rate was 87.1%.As for control group,among the 30 cases,3 cases were cured,4 cases were markedly effective,15 cases were effective and 8 cases were ineffective, the total effective rate was 73.3%.The treated group was superior to control group in term of effectiveness on clinical outcome(P＜0.05).
2.7 The correlation analysis of clinical comprehensive efficacy and the extent of disease,the severity of disease:There was no correlation between clinical comprehensive efficacy and the extent of disease(P＞0.05).Clinical comprehensive efficacy was negatively correlated with the severity of disease(P＜0.01),the more simple the disease is,the more effective the treatment is.
2.8 The result of adverse reactions:During treatment the treated group had no obvious side effects,while one cases in control group occurred leukopenia, and western medicine was suspended after one course of treatment,no special treatment was given.
Conclusions:
Animal experiments have shown that:the combination of Changdiqing and Changyanqing can significantly relief symptoms such as diarrhea and hematochezia,reduce the ulcer index of colonic mucosa,improve the pathomorphology,increase SOD activity in serum and tissues of colon,and decrease the level of MDA in rats with experimental UC.
Clinical study results have shown that:the method of removing heat and dispersing dampness in treating active mild and moderate UC belonging to wetness-heat of large intestine had significant clinical modifications with decrease of ESR,disappearance of fecal occult blood and improvements of cardinal symptom and colon mucosal lesions.The treated group was superior to the control group in term of measurements by Chinese medicine syndromes efficacy and clinical comprehensive efficacy.Results from this study have demonstrated that Changyanqing and Changdiqing combination therapy in treating UC can modify inflammatory inflammation,enhance the protective effect on mucosa cells and promote ulcer healing,through the mechanisms of increasing SOD activity and decreasing MDA level in serum and tissues of the colon.
近年来溃疡性结肠炎(ulcerative colitis,UC)在我国的发病率呈逐渐升高趋势,且被认为是结肠癌的癌前病变,已被世界卫生组织列为现代难治病之一。因其病因和发病机制尚未完全阐明,目前尚无根治办法。西药治疗本病,存在着疗效不理想及副作用较大等缺点,影响了病人的依从性,因此努力寻找临床疗效显著且副作用小的治疗方法是当务之急。在全面总结前期大量临床研究和实验研究的基础上,我们提出UC的病机特点,活动期以大肠湿热为主,治疗当以清热祛湿为主;缓解期病机特点以脾胃气虚为主,治疗当以健脾益气为主,而气滞血瘀贯穿病程始终。为了凸现中医药治疗本病的特色及优势,我们以UC轻中度病例为突破口,对活动期UC予清热祛湿中药口服+保留灌肠,形成肠炎清1号方和肠涤清灌肠液,并将其作为院内制剂在广东省中医院使用十余年,临床疗效显著。近年来研究发现,氧自由基参与了UC疾病的发生发展过程,本研究通过动物实验观察清热祛湿法(肠涤清灌肠+肠炎清1号灌胃)对实验性UC大鼠结肠黏膜损伤指数、血清和结肠组织匀浆SOD活力和MDA含量的影响,探讨其作用机制;同时采取随机对照前瞻性的临床研究,对清热祛湿法治疗活动期轻中度大肠湿热型UC的临床疗效及其安全性作出科学评价,探索治疗本病的最佳方案,以进一步推广其在临床应用。
研究方法
本课题分为实验研究和临床研究两部分。
实验研究方法:选择SPF级健康成年雌性SD大鼠51只,先随机抽取8只大鼠作为正常组,不予造模,剩余的43只大鼠利用三硝基苯磺酸(TNBS)+乙醇溶液诱导出急性期UC大鼠模型,造模后第3天随机抽取2只解剖以观察造模是否成功。剩余的41只大鼠随机分为4组:模型组(空白组)11只;肠涤清组、肠涤清+肠炎清组、SASP组,每组10只。造模后第4天开始用药,正常组和模型组大鼠每日给予生理盐水灌胃+灌肠,其余3组分别给予肠涤清灌肠、肠涤清灌肠+肠炎清灌胃、SASP灌胃+灌肠治疗,疗程结束后观察大鼠一般情况、体重、结肠黏膜损伤指数、光镜下结肠黏膜病理形态、血清和结肠组织匀浆SOD活力及MDA含量的变化。疗程为2周。
临床研究方法:将符合纳入标准的活动期轻、中度大肠湿热型UC患者70例,随机分为治疗组35例,对照组35例。治疗组予肠炎清1号方口服+肠涤清灌肠,对照组予SASP口服+灌肠,观察两组患者治疗前后的临床症状及体征(包括腹泻、粘液血便、里急后重等)、舌象、脉象、ESR、CRP、大便潜血及结肠镜黏膜病变特点。疗程为4周。
研究结果
1实验研究结果
1.1大鼠一般情况改善:所有大鼠在造模后的第2天即出现稀烂便,随后相继出现粘液便、脓血便。模型组大鼠伴有反应迟钝,不喜活动,倦怠懒动、毛发凌乱、拱背、饮食饮水减少、体重减轻,甚至死亡现象。其他3个治疗组用药1周后大鼠粘液血便逐渐减少,活动逐渐增多,饮食饮水量逐渐增加,其中以肠涤清+肠炎清组大鼠症状改善最为显著。
1.2大鼠体重变化:肠涤清组与肠涤清+肠炎清组大鼠体重增长均较快,两组比较差异无统计学意义(P＞0.05);肠涤清组与肠涤清+肠炎清组大鼠体重增长同SASP组比较,差异均有统计学意义(P＜0.01);SASP组大鼠体重增长和模型组比较,差异无统计学意义(P＞0.05),SASP组大鼠体重增长较慢。
1.3大鼠结肠黏膜损伤指数(CMDI)变化:CMDI以模型组为最高,与正常组比较,差异有统计学意义(P＜0.01);经过治疗后3个用药组CMDI均有所下降,与模型组比较,差异均有统计学意义(P＜0.01);肠涤清+肠炎清组CMDI与肠涤清组、SASP组比较,差异均有统计学意义(P＜0.01);肠涤清组和SASP组CMDI比较,差异无统计学意义(P＞0.05)。
1.4大鼠血清和结肠组织匀浆SOD活力变化:各组大鼠血清和结肠组织匀浆SOD活力从高到低,依次为:正常组＞肠涤清+肠炎清组＞肠涤清组＞SASP组＞模型组,其中以肠涤清+肠炎清组大鼠SOD活力升高最为显著(与其他3组比较,均P＜0.01)。
1.5大鼠血清和结肠组织匀浆MDA含量变化:各组大鼠血清和结肠组织匀浆MDA含量从高到低,依次为:模型组＞SASP组＞肠涤清组＞肠涤清+肠炎清组＞正常组,其中以肠涤清+肠炎清组MDA含量下降最为显著(与其他3组比较,P＜0.05或P＜0.01)。
2临床研究结果
2.1治疗后两组患者ESR、CRP比较:治疗组有21例患者、对照组有22例患者复查ESR、CRP。治疗后两组患者ESR和CRP都有所下降,与治疗前比较,差异均有统计学意义(P＜0.05或P＜0.01)。治疗后,两组ESR比较,差异有统计学意义(P＜0.05),治疗组ESR降低优于对照组;两组CRP比较,差异无统计学意义(P＞0.05),两组疗效相当。
2.2治疗后两组患者大便潜血改善比较:对大便潜血的改善情况,治疗组优于对照组(P＜0.05)。
2.3治疗后两组患者主要症状积分比较:治疗组所有症状均有改善,与治疗前比较,差异均有统计学意义(P＜0.05或P＜0.01);对照组除肛门灼热和溲赤2个症状改善不明显外,其余6个症状均有改善,与治疗前比较,差异有统计学意义(P＜0.05或P＜0.01)。治疗后两组患者症状积分改善比较,治疗组对里急后重和溲赤症状的改善优于对照组(P＜0.01);而其它6个症状(腹泻、粘液血便、腹痛、腹胀、发热、肛门灼热)的改善,两组比较无显著性差异(P＞0.05)。
2.4两组患者中医证候疗效比较:治疗组临床痊愈7例,显效10例,有效12例,无效2例,总有效率为92.5%;对照组临床痊愈2例,显效5例,有效14例,无效9例,总有效率为70.0%,治疗组中医证候疗效优于对照组(P＜0.01)。
2.5治疗后两组患者结肠黏膜病变情况比较:治疗组有15例患者,对照组有18例患者复查肠镜,治疗组对结肠黏膜病变的改善优于对照组(P＜0.05)。
2.6两组患者临床综合疗效比较:治疗组完全缓解6例,显效9例,好转12例,无效4例,总有效率为87.1%;对照组完全缓解3例,显效4例,好转15例,无效8例,总有效率为73.3%,治疗组临床综合疗效优于对照组(P＜0.05)。
2.7临床综合疗效与病变范围、病情严重程度的相关性分析:临床综合疗效与病变范围无相关性(P＞0.05),与病情严重程度呈正相关(P＜0.01),病情越轻,临床疗效越显著。
2.8不良反应观察:用药期间治疗组未见明显毒副作用,对照组有1例患者出现白细胞减少,疗程结束后停用西药,未做特殊处理。
研究结论
1肠涤清+肠炎清可以显著改善UC大鼠的腹泻和便血情况,减轻结肠黏膜损伤指数,改善结肠黏膜的病理形态学情况,提高血清和结肠组织SOD活力,降低血清和结肠组织MDA含量。
2清热祛湿法治疗活动期轻中度大肠湿热型UC疗效确切,可以显著降低UC患者ESR,改善大便潜血、主要症状和结肠黏膜病变程度,中医证候疗效和临床综合疗效优于西药对照组。结合动物实验结果,考虑清热祛湿法治疗活动期UC的机制之一,在于减轻机体的脂质过氧化强度,提高血清和结肠组织中SOD活力,降低血清和结肠组织中MDA含量,从而增强对细胞的保护作用,促进炎症和溃疡的愈合。
Objective and Significance:
The incidence of ulcerative colitis(UC) has been steadily increased in China since last decades.UC has been considered as precancerous lesions of colon cancers and classified as one of refractory diseases in modern society by World Health Organization.The etiology and pathogenesis of UC have not been fully elucidated,so there is no radical treatment for UC.Treatment of UC by western medicine has some shortcomings,such as unsatisfied efficacy and considerable side effects,which reduce patients' compliance.Therefore, it urgently needs to find alternative treatments with significant clinical improvement and little adverse effects.Based on the results from large amounts of previous clinical and experimental studies,we propose the pathogenesis of UC from the Chinese traditional medicine point of view.The characteristic of active UC is mainly wetness-heat of large intestine while that of remission stage is largely deficiency of spleen-Qi and stomach-Qi.Treatment for the former is dependent on removing heat and dispersing dampness but treatment for the latter should strengthen the spleen and replenish Qi.Both acute and remission stages of UC have Qi-stagnancy and blood stasis.Chinese traditional medicines were applied to treat patients with mind and moderate UC which can reflect on their characteristics and advantages.Patients with UC at acute stage were treated with a combination of oral Changyanging 1 and enema Changdiging fluid.Both Changyanging 1 and Changdiging fluid have been used in TCM hospital of Guangdong province for more than 10 years.
Recent studies have demonstrated that oxygen-free radicals play a role in the pathogenesis of UC.To explore the therapeutic effects and mechanisms, we measured the effect of removing heat and dispersing dampness(treatment by combination of oral Changyanging 1 and enema Changdiging fluid) on colon mucosa damage index(CMDI),the dynamic changes of superoxide dismutase(SOD) activity and MDA level in serum and colon tissues of rats with experimental ulcerative colitis.By means of randomized controlled prospective clinical study,we also evaluated the clinical efficacy and safety of the combination of Changyanqing 1 and Changdiqing fluid in the treatment of UC.Results from these studies,we could demonstrate their effectiveness on the treatment of UC and facilitate their clinical application.
Methods:
This thesis included two parts:experiment study and clinical study.
Methods of experimental study:8 rats were randomly selected as the normal group from 51 healthy female Sprague-Dawley(SD) rats.Active UC was induced by trinitro-benzene-sulfonic acid(WNBS) and ethanol solution in 43 rats.Three days after establishing the model of UC,2 rats randomly selected were dissected in order to observe the success of model.The remainders(41 rats) were randomly divided into three model groups,i.e.,Changdiqing group, Changdiqing + Changyanqing group and salicylazosulfapyridine(SASP) group.Four days after establishing the model of UC,the rats in both normal and model groups were treated with normal Saline enema(NSE).Rats in the other 3 groups were treated with Changdiqing enema,Changdiqing enema plus Changyanqing garage,and SASP by gavage and enema,respectively.The protection mechanism of the method of removing heat and dispersing dampness was observed in terms of general condition,weight,CMDI,dynamic changes of SOD activity and MDA level in serum and tissues of colon.The course of treatment was 2 weeks.
Methods of clinical study:Seventy patients fulfilling the inclusion criteria were randomly divided into two groups.Thirty-five cases in experimental group were treated with the combination of oral Changyanqing 1 and enema Changdiqing fluid,while 35 cases in control group were treated with SASP by oral administration and enema.The clinical efficacies were evaluated by observing patients with clinical symptoms and signs(including diarrhea, mucous bloody stool,rectal tenesmus,etc.),the characteristics of tongue and pulse,by measuring ESR and CRP,and by detecting fecal occult blood and colon mucous.The course of treatment was 4 weeks.
Results:
1 The results of experimental study:
1.1 The improvement of general conditions in rats:Two days after establishing the model of UC,all rats had loose stools,followed by mucous stool and bloody purulent stool.Rats in model group were companied with slow response,lack of movement,tiredness,messy hair,hollow back,poor appetite and little drinking-water,lose weight,and even death.One week after medication,mucous bloody stool gradually reduced while physical activities gradually improved. Both diet-uptake and drinking-water were gradually increased in the rats of other three treatment groups.The improvement of symptoms was most significant in Changdiqing + Changyanqing group.
1.2 Weight changes in rats:The weight of rats had rapid growth in Changdiqing group and Changdiqing + Changyanqing group,but there was no significant difference in weight change between these groups(P＞0.05).Comparing Changdiqing group with SASP group,a significant difference in weight change was noted(P＜0.01).Comparing Changdiqing + Changyanqing group with SASP group, the difference in weight change was also statistically significant (P＜0.01).Comparing SASP group with model group,no significant difference in weight change was found(P＞0.05).Rats grew slower in SASP group.
1.3 CMDI changes in rats:CMDI was highest in model group,compared with normal group,the difference was statistically significant(P＜0.01).After treatment,CMDI declined in 3 treatment groups.Comparing the 3 treatment groups with model group,the differences were statistically significant (P＜0.01).Comparing Changdiqing + Changyanqing group with Changdiqing group and SASP group,the differences were statistically significant (P＜0.01).Comparing Changdiqing group with SASP group,no significant difference in CMDI was noted(P＞0.05).
1.4 Dynamic changes of SOD activity in rats serum and tissues of colon:Normal group had highest SOD activity,followed by Changdiqing + Changyanqing group, Changdiqing group,SASP group,and untreated model group.The increase of SOD activity was the most remarkable in Changdiqing + Changyanqing group,compared with the other 3 groups,the difference was statistically significant(P＜0.01).
1.5 Dynamic changes of MDA level in rats serum and tissues of colon:Dynamic changes of MDA level was as follows:model group＞SASP group＞Changdiqing group＞Changdiqing + Changyanqing group＞normal group.The decline of MDA level was the most notable in Changdiqing + Changyanqing group,compared with the other 3 groups,the differences were statistically significant(P＜0.05 or P＜0.01).
2 The results of clinical study:
2.1 The result of ESR,CRP:Twenty-one patients in treat group completed the measurements of ESR and CRP after treatment,while 22 patients in control group did.After treatment,both ESR and CRP were decreased when compared to those before treatment(P＜0.05 and P＜0.01 for ESR and CRP,respectively).ESR was significantly low in treated groups if compared to that in control group (P＜0.05).However,CRP had no significant change between treated and control groups.
2.2 The detection of fecal occult blood showed that the treat group was superior to the control group(P＜0.05).
2.3 Scoring for major symptoms:In treated group all symptoms have improved, compared to those before treatment,the differences were statistically significant(P＜0.05 or P＜0.01) In control group,in addition to rectum searing heat and short red urine,the improvement of other 6 symptoms were compared with before treatment,the difference was statistically significant (P＜0.05 or P＜0.01).After treatment,the improvement of rectal tenesmus and short red urine,the treat group was superior to the control group(P＜0.01).The improvement of other 6 symptoms,comparing the two groups,the difference was not statistically significant(P＞0.05).
2.4 Syndromes judged by Chinese traditional medicine standards:In treated group,among the 31 cases,7 cases were cured,lO cases were markedly effective, 12 cases were effective and 2 cases were ineffective,the total effective rate was 92.5%.As for control group,among the 30 cases,2 cases were cured, 5 cases were markedly effective,14 cases were effective and 9 cases were ineffective,the total effective rate was 70.0%.The treat group was superior to the control group in term of Chinese medicine syndromes efficacy(P＜0.05).
2.5 The result of examining colon mucosal lesions:Fifteen patients in treat group received colonoscopy after treatment,while18 patients in control group did.Pathologic examination showed that colon mucosal lesions in the treated group improved better than that in the control group(P＜0.05).
2.6 The result of clinical comprehensive efficacy:In treated group,among the 31 cases,6 cases were cured,9 cases were markedly effective,12 cases were effective and 4 cases were ineffective,the total effective rate was 87.1%.As for control group,among the 30 cases,3 cases were cured,4 cases were markedly effective,15 cases were effective and 8 cases were ineffective, the total effective rate was 73.3%.The treated group was superior to control group in term of effectiveness on clinical outcome(P＜0.05).
2.7 The correlation analysis of clinical comprehensive efficacy and the extent of disease,the severity of disease:There was no correlation between clinical comprehensive efficacy and the extent of disease(P＞0.05).Clinical comprehensive efficacy was negatively correlated with the severity of disease(P＜0.01),the more simple the disease is,the more effective the treatment is.
2.8 The result of adverse reactions:During treatment the treated group had no obvious side effects,while one cases in control group occurred leukopenia, and western medicine was suspended after one course of treatment,no special treatment was given.
Conclusions:
Animal experiments have shown that:the combination of Changdiqing and Changyanqing can significantly relief symptoms such as diarrhea and hematochezia,reduce the ulcer index of colonic mucosa,improve the pathomorphology,increase SOD activity in serum and tissues of colon,and decrease the level of MDA in rats with experimental UC.
Clinical study results have shown that:the method of removing heat and dispersing dampness in treating active mild and moderate UC belonging to wetness-heat of large intestine had significant clinical modifications with decrease of ESR,disappearance of fecal occult blood and improvements of cardinal symptom and colon mucosal lesions.The treated group was superior to the control group in term of measurements by Chinese medicine syndromes efficacy and clinical comprehensive efficacy.Results from this study have demonstrated that Changyanqing and Changdiqing combination therapy in treating UC can modify inflammatory inflammation,enhance the protective effect on mucosa cells and promote ulcer healing,through the mechanisms of increasing SOD activity and decreasing MDA level in serum and tissues of the colon.
引文
[1]Lakatos PL.Recent trends in the epidemiology of inflammatory bowel diseases:up or down? World J Gastroenterol,2006;12(38):6102-6108.
[2]Lakatos L,Lakatos PL.Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J,2006;82:332-337.
[3]中国炎症性肠病协作组,王玉芳,欧阳钦.3100例溃疡性结肠炎住院病例回顾分析.中华消化杂志,2006;26(6):368-372.
[4]王碧辉.溃疡性结肠炎中西医治疗进展.世界华人消化杂志,1999;7(2):177-179.
[5]Eaden J,Abrams K,Ekbom A,et al.Colorectal cancer prevention in ulcerative colitis:a case-control study.Aliment Pharmacol Ther,2000;14(2):145-153
[6]陈曼湖,胡品津.炎症性肠病的研究进展,广州:广东科技出版社,2006,第1版:73-75.
[7]Farmer RG,Michener WM,Mortimer EA.Studies of family history among patients with inflammatory bowel disease.Clin Gastroenterol,1980;9(2):271-277.
[8]Yang H,McElree C,Roth MP,et al.Familial empirical risks for inflammatory bowel disease:differences between Jews and non-Jews.Gut,1993;34(4):517-524.
[9]刘桂敏,王秀坤.溃疡性结肠炎的遗传倾向.中华消化杂志,1997;17(4):188.
[10]欧阳钦.溃疡性结肠炎的研究进展.现代消化及介入诊疗,2008;13(2):100-103.
[11]Kleessen B,Kroesen AJ,Buhr HJ,et al.Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls.Scand J Gastroenterol,2002;37(9):1034-1041.
[12]潘国宗.溃疡性结肠炎的病因和发病机制.现代消化及介入诊疗,2008;13(2):100-105.
[13]Peluso I,Pallone F,Monteleone G.Interleukin-12 and Th1 immune response in Crohn's disease:pathogenetic relevance and therapeutic implication.World J Gastroenterol,2006;12(35):5606-5610.
[14]Sartor RB.Intestinal microflora in human and experimental inflammatory bowel disease.Curr Opin Gastroenterol,2001;17(4):324-330.
[15]Borruel N,Carol M,Casellas F,et al.Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.Gut,2002;51(5):659-664.
[16]Kruis W.Review article:antibiotics and probiotics in inflammatory bowel disease.Aliment Pharmacol Ther,2004;20 Suppl 4:75-78
[17]Cameron EA,Binnie JA,Balan K,et al.Oral prednisolone metasulphobenzoate in the treatment of active ulcerative colitis.Scand J Gastroenterol,2003;38(5):535-537.
[18]Campieri M,Gionchetti P.Bacteria as the cause of ulcerative colitis.Gut 2001;48(1):132-135.
[19]Nakamura RM,Barry M.Serologic markers in inflammatory bowel disease (IBD),Med Lab Obs,2001;33:8-15.
[20]王晶晶,王民玉,赵霞.溃疡性结肠炎患者外周血T细胞亚群的检测及意义.山东医药,2004;44(1):8.
[21]Schreiber S.Experimental immunomodulatory therapy of inflammatory bowel disease.Neth J Med,1998;53(6):24-31.
[22]张文俊,许国铭,李兆申,等.血清白细胞介素1 β与溃疡性结肠炎的关系.第二军医大学学报,2002;23(12):1345-1347.
[23]Van Assche G,Dalle I,Noman M,et al.A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.Am J Gastroenterol,2003;98(2):369-376.
[24]丁伟群,林庚金,徐三荣,等.溃疡性结肠炎发病中白介素水平的变化.复旦学报:医学版,2001;28(4):330-333.
[25]Willems J,Joniau M,Cinque S,et al.Human granulocyte chemotactic peptide (IL-8) as a specific neutrophil degranulator:comparison with other monokines.Immunology,1989;67(4):540-542.
[26]王晓娣,董恩钰.白介素-17在溃疡性结肠炎表达的研究.中华消化杂志,2001;21(11):673-676.
[27]Ebert EC.Tumour necrosis factor-alpha enhances intraepithelial lymphocyte proliferation and migration.Gut,1998;42(5):650-655.
[28]Tagore A,Gonsalkorale WM,Pravica V,et al.Interleukin-10(IL-10)genotypes in inflammatory bowel disease.Tissue Antigen,1999;54(4):386-390.
[29]Jijon HB,Churchill T,Malfair D,et al.Inhibition of poly(hDP-ribose)polymerase attenuates inflammation in a model of chronic colitis.Am J Physiol Gastrointest Liver Physiol,2000;279(3):641-651.
[30]周宇,叶文桃,麦海妍,等.白介素13和一氧化氮在溃疡性结肠炎的作用及意义. 胃肠病学和肝病学杂志,2004;13(3):319-321.
[31]张文俊,李兆申,许国铭等.细胞凋亡调控蛋白Bcl-2和Bax在溃疡性结肠炎表达中的研究[J].中华消化内镜杂志,2003;20(4):262-264.
[32]Iwamoto M,Koji T,Makiyama K,et al.Apoptosis of crypt epithelial cells in ulcerative colitis.J Pathol,1996;180(2):152-160.
[33]费保莹.细胞粘附分子与炎症性肠病.国外医学:消化系疾病分册,1999;19(1):15-17.
[34]梁华平,徐祥,王正国.重视以核因子-κ B为抗炎靶点的拮抗策略.感染、炎症、修复,2005;6(2):67-70.
[35]陈吉,高美丽,白晓茹,等.核因子κ B和细胞因子在溃疡性结肠炎中的表达及其意义.世界华人消化杂志,2009;17(2):209-212.
[36]Miller MJ,Angeles FM,Reuter BK,et al.Dietary antioxidants protect gut epithelial cells from oxidant-induced apoptosis.BMC Complement Alternative Med,2001;1:11.
[37]金惠铭.病理生理学,北京:人民卫生出版社,2000,第5版:150.
[38]郝志明,苌新民,王利公.溃疡性结肠炎患者血清MDA及SOD的变化.胃肠病学和肝病学杂志,2000;9(2):124-125.
[39]Mizoguchi H,Ogawa Y,Kanatsu K,et al.Protective effect of rebamipide on indomethacin-induced intestinal damage in rats.J Gastroenterol Hepatol,2001,16(10):1112-1119.
[40]刘建生,田怡,张晓红,等.溃疡性结肠炎与一氧化氮和氧自由基关系及丹参治疗作用研究.中国医师杂志,2006;8(8):1040-1042.
[41]江学良,权启镇,孙自勤,等.抗栓灵含片治疗伴有血小板活化的难治性溃疡性结肠炎.世界华人消化杂志,2003;11(8):1214-1218.
[42]Vrij AA,Rijken J,Van Wersch JW,et al.Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis.Eur J Clin Invest,2000;30(3):188-194.
[43]黄智勇,曾国琼,谭旭东,等.血小板激活与活动期发生溃疡性结肠炎的关系.中国基层医药,2006;13(3):386-387.
[44]潘国宗,曹世植.现代胃肠病学(上册),北京:科学出版社,1994,第1版:161-168.
[45]Mawdsley JE,Rampton DS.Psychological stress in IBD:new insights into pathogenic and therapeutic implications.Gut,2005;54(10):1481-1491.
[46]刘凤芹,楚更五,李子华,等.心理因素与溃疡性结肠炎.健康心理学杂志,2001;9(4):307-308.
[47]李强,鞠应东,王倩,等.抗抑郁药及心理疗法在溃疡性结肠炎治疗中的作用.山 东医药,2005;45(18):56
[48]Nakamura T,Nagahori M,Kanai T,et al.Current pharmacological therapies and emerging alterative in the treatment of ulcerative colitis.Digestion,2008:77(suppl 1):36-41.
[49]Bianchi Porto G,Cassinotti A,Ferrara E,et al.Review article:the management of steroid dependency in ulcerative colitis.Aliment Pharmacol Ther,2007;26(6):779-794.
[50]欧阳钦.炎症性肠病诊治新进展.当代医学,2001;7(5):36-40.
[51]Rutgeerts P.A critical assessment of new therapies in inflammatory bowel disease J.J Gastroenterol Hepatol,2002:17 Supple:S176-185.
[52]Derijks LJ,Gilissen LP,Hooymans PM,et al.Review article:thiopurines in inflammatory bowel disease.Aliment Pharmcol Ther,2006;24(5):715-729.
[53]Evans RC,Shim Wong V,Morris AI,et al.Treatment of corticosteroid resistant ulcerative colitis with heparin A report of 16 cases.Aliment Pharmacol Ther,1997;11(6):1037-1040.
[54]贺国斌,欧阳钦.低分子量肝素对DSS诱导小鼠结肠炎的疗效观祭.四川大学学报(医学版),2003;34(4):701-703.
[55]张克平.溃疡性结肠炎的抗凝治疗.中华现代医学与临床,2005;3(7):16-17.
[56]欧阳钦.炎症性肠病发病机制研究对治疗的指导作用.四川医学,2003;24(6):551-552.
[57]Kato K,Mizuno S,Umesaki Y,et al.Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.Aliment Pharmacol Ther,2004;20(10):1133-1141.
[58]杨春辉,艾江,王久英.丽珠肠乐治疗溃疡性结肠炎的临床研究.牡丹江医学院学报,2008;29(1):14-16.
[59]Baumgart DC,Sandborn WJ.Inflammatory bowel disease:clinical aspects and established and evolving therapies.Lancet,2007:369(9573):1641-1657.
[60]Oldenburg B,Hommes D.Biological therapies in inflammatory bowel disease:top-down or bottom-up? Curr Opin Gastroenterol 2007:23(4):395-399.
[61]Rutgeerts P,Sandborn WJ,Feagan BG,et al.Infliximab for induction and maintenance therapy for ulcerative colitis.N Engl J Med,2005:353(23):2462-2476.
[62]易季云,夏冰、黄梅芳,等.鼠溃疡性肠炎模型的观察.新消化病学杂志,1997;5(11):721-722.
[63]夏冰,黄梅芳,付苓,等.细胞免疫反应性溃疡性结肠炎模型.中华实验外科杂志, 1992;9(3):130-131.
[64]徐叔云.药理学实验方法,北京:人民卫生出版社,1991,第1版:1160-1162.
[65]陈治水,聂志伟,张志清,等.溃疡性结肠炎动物模型的复制与健脾灵复健作用的研究:对免疫发病机制的探讨.中医药学报,1990;(2):49-51.
[66]赵辉,周建中.溃疡性结肠炎的中药治疗及对结肠粘液影响的研究.北京医科大学学报,1990;22(3):197-199.
[67]黄梅芳,傅苓.溃疡性结肠炎的细胞毒实验研究及临床探讨.中华消化杂志,1990;10(5):268-270.
[68]黄永年,张元德,刑玉馥.大鼠溃疡性结肠炎模型的建立与观察.中华病理学杂志,1995:24(6):392.
[69]Bicks RO,Rosenberg EW.A chronic,delayed hypersensitivity reaction in the guinea pig colon.Gastroenterology,1964;46(5):543-549.
[70]Rabin BS,Rogers SJ.A cell-mediated immune model of inflammatory bowel disease in the rabbit.Gastroenterology,1978;75(1):29-33.
[71]王群英,陈村龙,王继德,等.葡聚糖硫酸钠致溃疡性结肠炎小鼠模型的建立.第一军医大学学报,2002;22(7):608-610.
[72]Sung TS,La JH,Kim Tw,et al.Alteration of nitrergic neuromuscular transmission as a result of acute experimental colitis in rat.J Vet Sci,2006:7(2):143-150.
[73]张涛,谢建群.大鼠溃疡性结肠炎模型的实验研究.中国中西医结合消化杂志,2006;14(4):240-242.
[74]Fidler JM.Induction of hapten-specific immunological tolerance and immunity in B lymphocytes.Ⅶ.Correlation between trinitrobenzenesulfonic acid administration,serum trinitrophenyl content,and level of tolerance.Cell Immunol,1985;94(1):285-291.
[75]欧阳钦.我国炎症性肠病研究的概况和策略.四川医学,2005;26(4):355-356.
[76]杨爱学,江魏.中医药治疗溃疡性结肠炎临床疗效的Meta分析.中医杂志,2006;47(4):283-284.
[77]吕永慧.溃疡性结肠炎的研究近况.中国中西医结合脾胃杂志,1996;16(2):116-119.
[78]危北海.中医脾胃学说应用研究,北京:北京出版社,1993,第1版:276-330.
[79]张正利,蔡淦,师万西.溃疡性结肠炎中医治疗及理论探讨.陕西中医,2001;22(7):405-406.
[80]全国肛肠学会溃疡性结肠炎学术研讨会.慢性非特异性溃疡性结肠炎诊断分型及治疗标准(讨论稿).中国医药学报,1988;(4):71.
[81]中国中西医结合学会消化系统疾病专业委员会第四届全国学术交流会.慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗效标准(试行方案).中国中西医结合杂志,1994;14(4):239-240.
[82]郑筱萸.中药新药临床研究指导原则,北京:中国医药科技出版社,2002,第1版:129-131.
[83]陈治水,危北海,张万岱等.溃疡性结肠炎中西医结合诊治方案(草案).中国中西医结合消化杂志,2005;13(4):133-135.
[84]李乾构,周学文,单兆伟.中医消化病诊疗指南,北京:中国中医药出版社,2006,第1版:80一84.
[85]谭丹.溃疡性结肠炎的辨证分型治疗浅析.中医药学刊,2001;19(6):555.
[86]杨小波.溃疡性结肠炎中医辨治理论模型的重构与初步确证[D].广州中医药大学,2006.
[87]王新月.溃疡性结肠炎分期辨治体会.江苏中医药,2006;27(1):10-11.
[88]李乾构.中医药治疗溃疡性结肠炎的思路.北京中医,2004;23(3):149-150.
[89]陈建芳,杨志贤.辨证结合辨病治疗溃疡性结肠炎80例.南京中医药大学学报,2002;18(3):184-185.
[90]江学良,崔慧斐.中国溃疡性结肠炎10218例的特点.世界华人消化杂志,2001;9(8):869-873.
[91]幸良铨.中医药肠道给药的研究和展望.中医药信息,1987;1:16.
[92]张学斌,罗云坚,黄穗平等.肠涤清治疗慢性溃疡性结肠炎104例临床观察.中药新药与临床药理,2002;13(5):275.
[93]张燕,刘鑫,李燕宁.苦菊液灌肠治疗溃疡性结肠炎30例.实用中医内科杂志,2004;18(2):157.
[94]陈来恩.溃结清灌肠液治疗溃疡性结肠炎150例.中医研究,2006;19(3):42-43.
[95]马红学.针灸治疗溃疡性结肠炎72例观察.山西中医,2008;24(8):28、30.
[96]杜艳茹,张艳霞,孙胜振,等.药穴结合治疗溃疡性结肠炎89例临床疗效观察.中医杂志,2008;49(4):314-316.
[97]吕明,刘晓艳.推拿三步九法结合针灸治疗慢性溃疡性结肠炎46例.辽宁中医杂志,2005;32(9):951.
[98]赵维杰.穴位埋线治疗溃疡性结肠炎的临床研究.中国中医药杂,2005;3(1):975-977.
[99]杨辉.热瘀散对溃疡性结肠炎胃肠湿热型大鼠模型MDA、SOD、IL-6的影响.广西中医药,2007;30(4):54-55.
[100]吕冠华,劳绍贤.脾胃湿热证动物模型的建立与评价.广州中医药大学学报, 2005;22(3):231-235.
[101]谷松,关庆增,明彩荣,等.溃疡性结肠炎肝郁大鼠模型的实验研究.辽宁中医杂志,2005;32(11):1210-1211.
[102]唐已婷,陈家旭.束缚应激与中医肝的关系.中国医药学报,2002;17(2):82-83.
[103]乔明琦,张惠云,陈雨振,等.肝郁证动物模型研究的理论思考.中国医药学报,1997;12(5):42-44.
[104]王晓洁,梁建光,万军利.建立大鼠脾虚型溃疡性结肠炎病理模型的实验.烟台师范学院学报:自然科学版,1999;15(2):151-154.
[105]曲颖,胡大康.纳米中药对脾虚型溃疡性结肠炎动物模型的影响.中国热带医学,2007;7(9):1552-1553、1560.
[106]顾立刚,郭学志.大鼠溃疡性结肠炎肝郁脾虚证模型的研究.北京中医药大学学报,1999;22(2):21-23.
[107]丁晓刚.黄芩汤有效成分配方对大鼠实验性溃疡性结肠炎的免疫调节作用.中医药学刊,2003;21(1):126-127.
[108]田军彪,单兆伟,刘建平,等.芪仙安肠方对大鼠溃疡性结肠炎的治疗作用及机制.河北中医,2008;30(4):424-427.
[109]张道权,吴正祥,吴强.丹参注射液对三硝基苯磺酸诱导的大鼠溃疡性结肠炎的保护作用机制.贵阳中医学院学报,2007;29(3):67-69.
[110]高亚菲,朱昭明,李旭.慢性溃疡性结肠炎中医“证”与有关免疫生化物质关系的探讨.西安医科大学学报,1996;17(3):356-358.
[111]慕澜,魏连波,罗炳德,等.大肠湿热证模型大鼠血清部分白细胞介素含量的变化.中国中西医结合消化杂志,2003;11(5):262-263.
[112]刘少琼,陈华兵,付学源,等.湿热内蕴与脾肾阳虚型溃疡性结肠炎患者Th1/Th2的状态.南华大学学报·医学版,2007;35(5):688-690.
[113]Morris GP,Beck PL,Herridge MS,et al.Hapten-induced model of chronic inflammation and ulceration in the rat colon.Gastroenterology,1989;96(3):795-803.
[114]施新猷.医用实验动物学,西安:陕西科学技术出版社,1989,第1版.
[115]Vilaseca J,Salas A,Guarner F,et al.Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis.Gut,1990;31(5):539-544.
[116]陈英群,董福轮,马贵同.三硝基苯磺酸诱导大鼠溃疡性结肠炎的实验研究.同济大学学报:医学版,2006;27(6):31-33.
[117]钟英强,朱兆华,幸连春.活动期溃疡性结肠炎活检黏膜的病理组织学特征、 分级及其与疾病程度的关系.中华消化杂志,2003;23(7):414-417.
[118]马春曦,李志晋,詹丽英,等.溃疡性结肠炎大鼠肠组织中MDA、SOD、损伤指数的动态变化及其相关性研究.江西医学院学报,2005;45(3):4-6.
[119]李竹.新编实用医学统计方法与技能,中国医药科技出版社,1997,第1版:182-183.
[120]王庶.大黄的研究.中国医学研究与临床,2004;2(4):68-69.
[121]李玉敏.大黄的药理作用机理探讨.河南医药信息,2002;10(6):37.
[122]乔立新,赵扶叶,孔祥梅,等.愈疡液的研制及应用.中国药房,1999;10(4):159.
[123]田代华.实用中医对药方,北京:人民卫生出版社,2000,第1版:687、697.
[124]崔红霞,朱友娟,邱建华.复方黄柏汤灌肠揉灸治疗溃疡性结肠炎48例.齐鲁药事,2008;27(10):631-632.
[125]郑继昌.白及头翁汤保留灌肠治疗溃疡性结肠炎83例.实用中西医结合临床,2008;8(5):86
[126]张金炎.败酱草为主治疗慢性溃疡性结肠炎.中医杂志,2002;43(12):892.
[127]侯家玉.中药药理学,北京:中国中医药出版社,2002,第1版:45.
[128]时维静,俞浩,孙海明,等.白头翁汤及其拆方抗腹泻、抗炎作用的实验研究.中国中医药科技,2007;14(4):257-258.
[129]唐尚友,王捷虹,任海勇,等.白头翁汤加味治疗溃疡性结肠炎68例临床观察.中国中医基础医学杂志,2006;12(11):848-849.
[130]徐建军,季峰,陈建永,等.芍药汤加减治疗慢性溃疡性结肠炎疗效观察.浙江中医杂志,2007;42(6):323-324.
[131]项平,徐富星,欧平安.溃疡性结肠炎486例结肠检查的评价和分析.中华消化杂志,1996:16(3):136-138.
[132]Vermeire S,Van Assche G,Rutgeers P.The role of C-reactive protein as an infalmmatroy marker in gastrointestinal diseases.Nat Clin Pract Gastro -enterol Hepatol,2005;2(12):580-586.
[133]Vermeire S,Van Assche G,Rutgeers P.C-reactive protein as an marker for inflammatory bowel disease.Inflam Bowel Dis,2004;10(5):661-665.
[134]Poullis AP,Zar S,Sundaram KK,et al.A new highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation and diarrhea-predominant functional bowel disorders.Eur J Gastroenterol Hepatol,2002;14(4):409-412.
[135]Solem CA,Loftus EV Jr,Tremaine WJ,et al.Correlation of C-reactive protein with clinical,endoscopic,histologic,and radiographic activity inflammatory bowel disease.Inflamm Bowel Dis,2005;11(8):707-712.
[136]谢芳,刘占举.C反应蛋白对溃疡性结肠炎患者的临床严重程度评价.四川医学,2008;29(2):188-199.
[137]徐跃荣,卢放根.溃疡性结肠炎患者血CRP活性与ESR的变化及临床意义.中华临床新医学,2004;4(11):966-967.
[2]Lakatos L,Lakatos PL.Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J,2006;82:332-337.
[3]中国炎症性肠病协作组,王玉芳,欧阳钦.3100例溃疡性结肠炎住院病例回顾分析.中华消化杂志,2006;26(6):368-372.
[4]王碧辉.溃疡性结肠炎中西医治疗进展.世界华人消化杂志,1999;7(2):177-179.
[5]Eaden J,Abrams K,Ekbom A,et al.Colorectal cancer prevention in ulcerative colitis:a case-control study.Aliment Pharmacol Ther,2000;14(2):145-153
[6]陈曼湖,胡品津.炎症性肠病的研究进展,广州:广东科技出版社,2006,第1版:73-75.
[7]Farmer RG,Michener WM,Mortimer EA.Studies of family history among patients with inflammatory bowel disease.Clin Gastroenterol,1980;9(2):271-277.
[8]Yang H,McElree C,Roth MP,et al.Familial empirical risks for inflammatory bowel disease:differences between Jews and non-Jews.Gut,1993;34(4):517-524.
[9]刘桂敏,王秀坤.溃疡性结肠炎的遗传倾向.中华消化杂志,1997;17(4):188.
[10]欧阳钦.溃疡性结肠炎的研究进展.现代消化及介入诊疗,2008;13(2):100-103.
[11]Kleessen B,Kroesen AJ,Buhr HJ,et al.Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls.Scand J Gastroenterol,2002;37(9):1034-1041.
[12]潘国宗.溃疡性结肠炎的病因和发病机制.现代消化及介入诊疗,2008;13(2):100-105.
[13]Peluso I,Pallone F,Monteleone G.Interleukin-12 and Th1 immune response in Crohn's disease:pathogenetic relevance and therapeutic implication.World J Gastroenterol,2006;12(35):5606-5610.
[14]Sartor RB.Intestinal microflora in human and experimental inflammatory bowel disease.Curr Opin Gastroenterol,2001;17(4):324-330.
[15]Borruel N,Carol M,Casellas F,et al.Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.Gut,2002;51(5):659-664.
[16]Kruis W.Review article:antibiotics and probiotics in inflammatory bowel disease.Aliment Pharmacol Ther,2004;20 Suppl 4:75-78
[17]Cameron EA,Binnie JA,Balan K,et al.Oral prednisolone metasulphobenzoate in the treatment of active ulcerative colitis.Scand J Gastroenterol,2003;38(5):535-537.
[18]Campieri M,Gionchetti P.Bacteria as the cause of ulcerative colitis.Gut 2001;48(1):132-135.
[19]Nakamura RM,Barry M.Serologic markers in inflammatory bowel disease (IBD),Med Lab Obs,2001;33:8-15.
[20]王晶晶,王民玉,赵霞.溃疡性结肠炎患者外周血T细胞亚群的检测及意义.山东医药,2004;44(1):8.
[21]Schreiber S.Experimental immunomodulatory therapy of inflammatory bowel disease.Neth J Med,1998;53(6):24-31.
[22]张文俊,许国铭,李兆申,等.血清白细胞介素1 β与溃疡性结肠炎的关系.第二军医大学学报,2002;23(12):1345-1347.
[23]Van Assche G,Dalle I,Noman M,et al.A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.Am J Gastroenterol,2003;98(2):369-376.
[24]丁伟群,林庚金,徐三荣,等.溃疡性结肠炎发病中白介素水平的变化.复旦学报:医学版,2001;28(4):330-333.
[25]Willems J,Joniau M,Cinque S,et al.Human granulocyte chemotactic peptide (IL-8) as a specific neutrophil degranulator:comparison with other monokines.Immunology,1989;67(4):540-542.
[26]王晓娣,董恩钰.白介素-17在溃疡性结肠炎表达的研究.中华消化杂志,2001;21(11):673-676.
[27]Ebert EC.Tumour necrosis factor-alpha enhances intraepithelial lymphocyte proliferation and migration.Gut,1998;42(5):650-655.
[28]Tagore A,Gonsalkorale WM,Pravica V,et al.Interleukin-10(IL-10)genotypes in inflammatory bowel disease.Tissue Antigen,1999;54(4):386-390.
[29]Jijon HB,Churchill T,Malfair D,et al.Inhibition of poly(hDP-ribose)polymerase attenuates inflammation in a model of chronic colitis.Am J Physiol Gastrointest Liver Physiol,2000;279(3):641-651.
[30]周宇,叶文桃,麦海妍,等.白介素13和一氧化氮在溃疡性结肠炎的作用及意义. 胃肠病学和肝病学杂志,2004;13(3):319-321.
[31]张文俊,李兆申,许国铭等.细胞凋亡调控蛋白Bcl-2和Bax在溃疡性结肠炎表达中的研究[J].中华消化内镜杂志,2003;20(4):262-264.
[32]Iwamoto M,Koji T,Makiyama K,et al.Apoptosis of crypt epithelial cells in ulcerative colitis.J Pathol,1996;180(2):152-160.
[33]费保莹.细胞粘附分子与炎症性肠病.国外医学:消化系疾病分册,1999;19(1):15-17.
[34]梁华平,徐祥,王正国.重视以核因子-κ B为抗炎靶点的拮抗策略.感染、炎症、修复,2005;6(2):67-70.
[35]陈吉,高美丽,白晓茹,等.核因子κ B和细胞因子在溃疡性结肠炎中的表达及其意义.世界华人消化杂志,2009;17(2):209-212.
[36]Miller MJ,Angeles FM,Reuter BK,et al.Dietary antioxidants protect gut epithelial cells from oxidant-induced apoptosis.BMC Complement Alternative Med,2001;1:11.
[37]金惠铭.病理生理学,北京:人民卫生出版社,2000,第5版:150.
[38]郝志明,苌新民,王利公.溃疡性结肠炎患者血清MDA及SOD的变化.胃肠病学和肝病学杂志,2000;9(2):124-125.
[39]Mizoguchi H,Ogawa Y,Kanatsu K,et al.Protective effect of rebamipide on indomethacin-induced intestinal damage in rats.J Gastroenterol Hepatol,2001,16(10):1112-1119.
[40]刘建生,田怡,张晓红,等.溃疡性结肠炎与一氧化氮和氧自由基关系及丹参治疗作用研究.中国医师杂志,2006;8(8):1040-1042.
[41]江学良,权启镇,孙自勤,等.抗栓灵含片治疗伴有血小板活化的难治性溃疡性结肠炎.世界华人消化杂志,2003;11(8):1214-1218.
[42]Vrij AA,Rijken J,Van Wersch JW,et al.Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis.Eur J Clin Invest,2000;30(3):188-194.
[43]黄智勇,曾国琼,谭旭东,等.血小板激活与活动期发生溃疡性结肠炎的关系.中国基层医药,2006;13(3):386-387.
[44]潘国宗,曹世植.现代胃肠病学(上册),北京:科学出版社,1994,第1版:161-168.
[45]Mawdsley JE,Rampton DS.Psychological stress in IBD:new insights into pathogenic and therapeutic implications.Gut,2005;54(10):1481-1491.
[46]刘凤芹,楚更五,李子华,等.心理因素与溃疡性结肠炎.健康心理学杂志,2001;9(4):307-308.
[47]李强,鞠应东,王倩,等.抗抑郁药及心理疗法在溃疡性结肠炎治疗中的作用.山 东医药,2005;45(18):56
[48]Nakamura T,Nagahori M,Kanai T,et al.Current pharmacological therapies and emerging alterative in the treatment of ulcerative colitis.Digestion,2008:77(suppl 1):36-41.
[49]Bianchi Porto G,Cassinotti A,Ferrara E,et al.Review article:the management of steroid dependency in ulcerative colitis.Aliment Pharmacol Ther,2007;26(6):779-794.
[50]欧阳钦.炎症性肠病诊治新进展.当代医学,2001;7(5):36-40.
[51]Rutgeerts P.A critical assessment of new therapies in inflammatory bowel disease J.J Gastroenterol Hepatol,2002:17 Supple:S176-185.
[52]Derijks LJ,Gilissen LP,Hooymans PM,et al.Review article:thiopurines in inflammatory bowel disease.Aliment Pharmcol Ther,2006;24(5):715-729.
[53]Evans RC,Shim Wong V,Morris AI,et al.Treatment of corticosteroid resistant ulcerative colitis with heparin A report of 16 cases.Aliment Pharmacol Ther,1997;11(6):1037-1040.
[54]贺国斌,欧阳钦.低分子量肝素对DSS诱导小鼠结肠炎的疗效观祭.四川大学学报(医学版),2003;34(4):701-703.
[55]张克平.溃疡性结肠炎的抗凝治疗.中华现代医学与临床,2005;3(7):16-17.
[56]欧阳钦.炎症性肠病发病机制研究对治疗的指导作用.四川医学,2003;24(6):551-552.
[57]Kato K,Mizuno S,Umesaki Y,et al.Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.Aliment Pharmacol Ther,2004;20(10):1133-1141.
[58]杨春辉,艾江,王久英.丽珠肠乐治疗溃疡性结肠炎的临床研究.牡丹江医学院学报,2008;29(1):14-16.
[59]Baumgart DC,Sandborn WJ.Inflammatory bowel disease:clinical aspects and established and evolving therapies.Lancet,2007:369(9573):1641-1657.
[60]Oldenburg B,Hommes D.Biological therapies in inflammatory bowel disease:top-down or bottom-up? Curr Opin Gastroenterol 2007:23(4):395-399.
[61]Rutgeerts P,Sandborn WJ,Feagan BG,et al.Infliximab for induction and maintenance therapy for ulcerative colitis.N Engl J Med,2005:353(23):2462-2476.
[62]易季云,夏冰、黄梅芳,等.鼠溃疡性肠炎模型的观察.新消化病学杂志,1997;5(11):721-722.
[63]夏冰,黄梅芳,付苓,等.细胞免疫反应性溃疡性结肠炎模型.中华实验外科杂志, 1992;9(3):130-131.
[64]徐叔云.药理学实验方法,北京:人民卫生出版社,1991,第1版:1160-1162.
[65]陈治水,聂志伟,张志清,等.溃疡性结肠炎动物模型的复制与健脾灵复健作用的研究:对免疫发病机制的探讨.中医药学报,1990;(2):49-51.
[66]赵辉,周建中.溃疡性结肠炎的中药治疗及对结肠粘液影响的研究.北京医科大学学报,1990;22(3):197-199.
[67]黄梅芳,傅苓.溃疡性结肠炎的细胞毒实验研究及临床探讨.中华消化杂志,1990;10(5):268-270.
[68]黄永年,张元德,刑玉馥.大鼠溃疡性结肠炎模型的建立与观察.中华病理学杂志,1995:24(6):392.
[69]Bicks RO,Rosenberg EW.A chronic,delayed hypersensitivity reaction in the guinea pig colon.Gastroenterology,1964;46(5):543-549.
[70]Rabin BS,Rogers SJ.A cell-mediated immune model of inflammatory bowel disease in the rabbit.Gastroenterology,1978;75(1):29-33.
[71]王群英,陈村龙,王继德,等.葡聚糖硫酸钠致溃疡性结肠炎小鼠模型的建立.第一军医大学学报,2002;22(7):608-610.
[72]Sung TS,La JH,Kim Tw,et al.Alteration of nitrergic neuromuscular transmission as a result of acute experimental colitis in rat.J Vet Sci,2006:7(2):143-150.
[73]张涛,谢建群.大鼠溃疡性结肠炎模型的实验研究.中国中西医结合消化杂志,2006;14(4):240-242.
[74]Fidler JM.Induction of hapten-specific immunological tolerance and immunity in B lymphocytes.Ⅶ.Correlation between trinitrobenzenesulfonic acid administration,serum trinitrophenyl content,and level of tolerance.Cell Immunol,1985;94(1):285-291.
[75]欧阳钦.我国炎症性肠病研究的概况和策略.四川医学,2005;26(4):355-356.
[76]杨爱学,江魏.中医药治疗溃疡性结肠炎临床疗效的Meta分析.中医杂志,2006;47(4):283-284.
[77]吕永慧.溃疡性结肠炎的研究近况.中国中西医结合脾胃杂志,1996;16(2):116-119.
[78]危北海.中医脾胃学说应用研究,北京:北京出版社,1993,第1版:276-330.
[79]张正利,蔡淦,师万西.溃疡性结肠炎中医治疗及理论探讨.陕西中医,2001;22(7):405-406.
[80]全国肛肠学会溃疡性结肠炎学术研讨会.慢性非特异性溃疡性结肠炎诊断分型及治疗标准(讨论稿).中国医药学报,1988;(4):71.
[81]中国中西医结合学会消化系统疾病专业委员会第四届全国学术交流会.慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗效标准(试行方案).中国中西医结合杂志,1994;14(4):239-240.
[82]郑筱萸.中药新药临床研究指导原则,北京:中国医药科技出版社,2002,第1版:129-131.
[83]陈治水,危北海,张万岱等.溃疡性结肠炎中西医结合诊治方案(草案).中国中西医结合消化杂志,2005;13(4):133-135.
[84]李乾构,周学文,单兆伟.中医消化病诊疗指南,北京:中国中医药出版社,2006,第1版:80一84.
[85]谭丹.溃疡性结肠炎的辨证分型治疗浅析.中医药学刊,2001;19(6):555.
[86]杨小波.溃疡性结肠炎中医辨治理论模型的重构与初步确证[D].广州中医药大学,2006.
[87]王新月.溃疡性结肠炎分期辨治体会.江苏中医药,2006;27(1):10-11.
[88]李乾构.中医药治疗溃疡性结肠炎的思路.北京中医,2004;23(3):149-150.
[89]陈建芳,杨志贤.辨证结合辨病治疗溃疡性结肠炎80例.南京中医药大学学报,2002;18(3):184-185.
[90]江学良,崔慧斐.中国溃疡性结肠炎10218例的特点.世界华人消化杂志,2001;9(8):869-873.
[91]幸良铨.中医药肠道给药的研究和展望.中医药信息,1987;1:16.
[92]张学斌,罗云坚,黄穗平等.肠涤清治疗慢性溃疡性结肠炎104例临床观察.中药新药与临床药理,2002;13(5):275.
[93]张燕,刘鑫,李燕宁.苦菊液灌肠治疗溃疡性结肠炎30例.实用中医内科杂志,2004;18(2):157.
[94]陈来恩.溃结清灌肠液治疗溃疡性结肠炎150例.中医研究,2006;19(3):42-43.
[95]马红学.针灸治疗溃疡性结肠炎72例观察.山西中医,2008;24(8):28、30.
[96]杜艳茹,张艳霞,孙胜振,等.药穴结合治疗溃疡性结肠炎89例临床疗效观察.中医杂志,2008;49(4):314-316.
[97]吕明,刘晓艳.推拿三步九法结合针灸治疗慢性溃疡性结肠炎46例.辽宁中医杂志,2005;32(9):951.
[98]赵维杰.穴位埋线治疗溃疡性结肠炎的临床研究.中国中医药杂,2005;3(1):975-977.
[99]杨辉.热瘀散对溃疡性结肠炎胃肠湿热型大鼠模型MDA、SOD、IL-6的影响.广西中医药,2007;30(4):54-55.
[100]吕冠华,劳绍贤.脾胃湿热证动物模型的建立与评价.广州中医药大学学报, 2005;22(3):231-235.
[101]谷松,关庆增,明彩荣,等.溃疡性结肠炎肝郁大鼠模型的实验研究.辽宁中医杂志,2005;32(11):1210-1211.
[102]唐已婷,陈家旭.束缚应激与中医肝的关系.中国医药学报,2002;17(2):82-83.
[103]乔明琦,张惠云,陈雨振,等.肝郁证动物模型研究的理论思考.中国医药学报,1997;12(5):42-44.
[104]王晓洁,梁建光,万军利.建立大鼠脾虚型溃疡性结肠炎病理模型的实验.烟台师范学院学报:自然科学版,1999;15(2):151-154.
[105]曲颖,胡大康.纳米中药对脾虚型溃疡性结肠炎动物模型的影响.中国热带医学,2007;7(9):1552-1553、1560.
[106]顾立刚,郭学志.大鼠溃疡性结肠炎肝郁脾虚证模型的研究.北京中医药大学学报,1999;22(2):21-23.
[107]丁晓刚.黄芩汤有效成分配方对大鼠实验性溃疡性结肠炎的免疫调节作用.中医药学刊,2003;21(1):126-127.
[108]田军彪,单兆伟,刘建平,等.芪仙安肠方对大鼠溃疡性结肠炎的治疗作用及机制.河北中医,2008;30(4):424-427.
[109]张道权,吴正祥,吴强.丹参注射液对三硝基苯磺酸诱导的大鼠溃疡性结肠炎的保护作用机制.贵阳中医学院学报,2007;29(3):67-69.
[110]高亚菲,朱昭明,李旭.慢性溃疡性结肠炎中医“证”与有关免疫生化物质关系的探讨.西安医科大学学报,1996;17(3):356-358.
[111]慕澜,魏连波,罗炳德,等.大肠湿热证模型大鼠血清部分白细胞介素含量的变化.中国中西医结合消化杂志,2003;11(5):262-263.
[112]刘少琼,陈华兵,付学源,等.湿热内蕴与脾肾阳虚型溃疡性结肠炎患者Th1/Th2的状态.南华大学学报·医学版,2007;35(5):688-690.
[113]Morris GP,Beck PL,Herridge MS,et al.Hapten-induced model of chronic inflammation and ulceration in the rat colon.Gastroenterology,1989;96(3):795-803.
[114]施新猷.医用实验动物学,西安:陕西科学技术出版社,1989,第1版.
[115]Vilaseca J,Salas A,Guarner F,et al.Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis.Gut,1990;31(5):539-544.
[116]陈英群,董福轮,马贵同.三硝基苯磺酸诱导大鼠溃疡性结肠炎的实验研究.同济大学学报:医学版,2006;27(6):31-33.
[117]钟英强,朱兆华,幸连春.活动期溃疡性结肠炎活检黏膜的病理组织学特征、 分级及其与疾病程度的关系.中华消化杂志,2003;23(7):414-417.
[118]马春曦,李志晋,詹丽英,等.溃疡性结肠炎大鼠肠组织中MDA、SOD、损伤指数的动态变化及其相关性研究.江西医学院学报,2005;45(3):4-6.
[119]李竹.新编实用医学统计方法与技能,中国医药科技出版社,1997,第1版:182-183.
[120]王庶.大黄的研究.中国医学研究与临床,2004;2(4):68-69.
[121]李玉敏.大黄的药理作用机理探讨.河南医药信息,2002;10(6):37.
[122]乔立新,赵扶叶,孔祥梅,等.愈疡液的研制及应用.中国药房,1999;10(4):159.
[123]田代华.实用中医对药方,北京:人民卫生出版社,2000,第1版:687、697.
[124]崔红霞,朱友娟,邱建华.复方黄柏汤灌肠揉灸治疗溃疡性结肠炎48例.齐鲁药事,2008;27(10):631-632.
[125]郑继昌.白及头翁汤保留灌肠治疗溃疡性结肠炎83例.实用中西医结合临床,2008;8(5):86
[126]张金炎.败酱草为主治疗慢性溃疡性结肠炎.中医杂志,2002;43(12):892.
[127]侯家玉.中药药理学,北京:中国中医药出版社,2002,第1版:45.
[128]时维静,俞浩,孙海明,等.白头翁汤及其拆方抗腹泻、抗炎作用的实验研究.中国中医药科技,2007;14(4):257-258.
[129]唐尚友,王捷虹,任海勇,等.白头翁汤加味治疗溃疡性结肠炎68例临床观察.中国中医基础医学杂志,2006;12(11):848-849.
[130]徐建军,季峰,陈建永,等.芍药汤加减治疗慢性溃疡性结肠炎疗效观察.浙江中医杂志,2007;42(6):323-324.
[131]项平,徐富星,欧平安.溃疡性结肠炎486例结肠检查的评价和分析.中华消化杂志,1996:16(3):136-138.
[132]Vermeire S,Van Assche G,Rutgeers P.The role of C-reactive protein as an infalmmatroy marker in gastrointestinal diseases.Nat Clin Pract Gastro -enterol Hepatol,2005;2(12):580-586.
[133]Vermeire S,Van Assche G,Rutgeers P.C-reactive protein as an marker for inflammatory bowel disease.Inflam Bowel Dis,2004;10(5):661-665.
[134]Poullis AP,Zar S,Sundaram KK,et al.A new highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation and diarrhea-predominant functional bowel disorders.Eur J Gastroenterol Hepatol,2002;14(4):409-412.
[135]Solem CA,Loftus EV Jr,Tremaine WJ,et al.Correlation of C-reactive protein with clinical,endoscopic,histologic,and radiographic activity inflammatory bowel disease.Inflamm Bowel Dis,2005;11(8):707-712.
[136]谢芳,刘占举.C反应蛋白对溃疡性结肠炎患者的临床严重程度评价.四川医学,2008;29(2):188-199.
[137]徐跃荣,卢放根.溃疡性结肠炎患者血CRP活性与ESR的变化及临床意义.中华临床新医学,2004;4(11):966-967.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |